NO20071439L - Fenantridin karbonylfenoler som cytokinmodulatorer - Google Patents

Fenantridin karbonylfenoler som cytokinmodulatorer

Info

Publication number
NO20071439L
NO20071439L NO20071439A NO20071439A NO20071439L NO 20071439 L NO20071439 L NO 20071439L NO 20071439 A NO20071439 A NO 20071439A NO 20071439 A NO20071439 A NO 20071439A NO 20071439 L NO20071439 L NO 20071439L
Authority
NO
Norway
Prior art keywords
cytokine modulators
phenanthridine
phenols
phenanthridine carbonyl
carbonyl phenols
Prior art date
Application number
NO20071439A
Other languages
English (en)
Norwegian (no)
Inventor
Robert John Steffan
William Jay Moore
Eugene John Trybulski
Albert John Molinari
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071439(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20071439L publication Critical patent/NO20071439L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20071439A 2004-09-02 2007-03-16 Fenantridin karbonylfenoler som cytokinmodulatorer NO20071439L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60678404P 2004-09-02 2004-09-02
PCT/US2005/031053 WO2006028875A1 (en) 2004-09-02 2005-08-30 Phenanthridine carbonyl phenols as cytokine modulators

Publications (1)

Publication Number Publication Date
NO20071439L true NO20071439L (no) 2007-04-23

Family

ID=35447362

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071439A NO20071439L (no) 2004-09-02 2007-03-16 Fenantridin karbonylfenoler som cytokinmodulatorer

Country Status (19)

Country Link
US (1) US7585871B2 (pt)
EP (1) EP1784391A1 (pt)
JP (1) JP2008511666A (pt)
KR (1) KR20070051877A (pt)
CN (1) CN101052623A (pt)
AR (1) AR050719A1 (pt)
AU (1) AU2005282829A1 (pt)
BR (1) BRPI0514860A (pt)
CA (1) CA2578933A1 (pt)
CR (1) CR8946A (pt)
EC (1) ECSP077366A (pt)
IL (1) IL181585A0 (pt)
MX (1) MX2007002624A (pt)
NI (1) NI200700066A (pt)
NO (1) NO20071439L (pt)
RU (1) RU2007108713A (pt)
TW (1) TW200616629A (pt)
WO (1) WO2006028875A1 (pt)
ZA (1) ZA200702701B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102532148B (zh) * 2011-12-22 2014-11-12 华中科技大学 葱莲中具有抗肿瘤作用的化合物及其分离制备方法和应用
US11034702B2 (en) * 2016-12-06 2021-06-15 Valorbec, Société en commandite Thienoisoquinolines and their derivatives for the treatment of cancer
JP7061772B2 (ja) * 2018-05-18 2022-05-02 国立大学法人千葉大学 フェナントリジン化合物の製造方法
WO2020117894A1 (en) * 2018-12-05 2020-06-11 The Board Of Trustees Of The University Of Illinois Isocarbostyril alkaloids and functionalization thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206225A (en) 1978-09-22 1980-06-03 Pfizer Inc. 2,10-Disubstituted dibenzo[b,d]pyrans and benzo[c]quinolines
US4228169A (en) 1979-06-26 1980-10-14 Pfizer Inc. 1,9-Dihydroxyoctahydrobenzo[c]quinolines and 1-hydroxyhexahydrobenzo[c]quinoline-9(8H)-ones as antiemetic agents
US5869483A (en) 1993-07-29 1999-02-09 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
WO2002005616A1 (en) 2000-07-14 2002-01-24 Altana Pharma Ag Novel 6-phenylphenanthridines
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200409759A (en) * 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides

Also Published As

Publication number Publication date
BRPI0514860A (pt) 2008-06-24
WO2006028875A1 (en) 2006-03-16
ECSP077366A (es) 2007-05-30
CN101052623A (zh) 2007-10-10
KR20070051877A (ko) 2007-05-18
EP1784391A1 (en) 2007-05-16
AU2005282829A1 (en) 2006-03-16
US20060058337A1 (en) 2006-03-16
IL181585A0 (en) 2007-07-04
TW200616629A (en) 2006-06-01
US7585871B2 (en) 2009-09-08
CR8946A (es) 2007-10-04
JP2008511666A (ja) 2008-04-17
NI200700066A (es) 2008-02-14
ZA200702701B (en) 2009-10-28
CA2578933A1 (en) 2006-03-16
AR050719A1 (es) 2006-11-15
MX2007002624A (es) 2007-04-27
RU2007108713A (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
JO2578B1 (en) Compounds Theophene benzimidazole
DE602004021472D1 (en) Pyrimiidinverbindungen
TW200608973A (en) Rapamycin polymorph Ⅱ and uses thereof
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
WO2007076260A3 (en) Farnesoid x receptor agonists
MX2010012074A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida.
MX2007006178A (es) Fenoles substituidos como agentes activos que inhiben la produccion del factor de crecimiento endotelial vascular.
WO2007005887A3 (en) Androgen receptor modulator compounds, compositions and uses thereof
MX2009012345A (es) Derivados de 3,3-espiroindolinona.
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
TNSN07196A1 (en) Potentiators of glutamate receptors
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
TW200722100A (en) A therapeutic agent for a β related disorders
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
TW200600494A (en) Bisphenyl compounds useful as vitamin d3 receptor agonists
PT2280706E (pt) Composições compreendendo derivados de benzeno que activam lipase de lipoproteína
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
MY140739A (en) 2, 6-quinolinyl derivatives, processes for preparing them and their uses
MXPA05008960A (es) Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
TW200619848A (en) Photoresist compositions
WO2004087652A3 (en) Imidazotriazine compounds
WO2005085236A3 (en) Caspase inhibitors and uses thereof
TW200621160A (en) Anti-termite agent

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application